Please login to the form below

Not currently logged in

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Gene therapy

A rapid round up from the frontline of pharma, biotech and healthcare

More encouraging data for Spark and Pfizer’s potential haemophilia B cure

Pfizer set to commence phase III trials

Positive mid-stage trial gives Allergy’s investors some welcome relief

A Pollinex packIts grass pollen vaccine showed a “highly significant” dose response

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

RocheLatest data could unlock a new patient population for the Swiss pharma giant’s injection

Immuno-oncology at ASCO: survival data, combinations and new indications

merck-keytruda-pembrolizumab-melanomaThe abstracts reveal heaps of strong contenders in the NSCLC category

AstraZeneca and Emulate advance ‘organs-on-chips’ research partnership

Organ-on-chipCompany advances partnership, aiming to integrate technology into full-scale R&D efforts

Another IO knockback as Tecentriq combo fails phase III trial

Roche Basel SwitzerlandThe bulk of CRC patients with MSS currently look set to be excluded from cancer immunotherapy

AZ’s Fasenra hit by COPD trial failure

AstraZeneca LogoResults give advantage to respiratory rivals GSK

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Eli Lilly HQArmo is developing IL-10 drugs for potential combination with established immunotherapies

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....